|
|
|
|
|
|---|
The Center of Excellence in HIV/AIDS & Cancer Virology, NCI
Despite significant advances in treatment, the number of newly diagnosed HIV-infected adults and children rose globally from ~3.9 million in 2004 to 4.3 million in 2006, and the number of deaths from ~2.7 million to 2.9 million over the same period. Moreover, the initial success of highly active antiretroviral therapy (HAART) in reducing viral burden is now threatened by the rapid emergence of drug-resistant virus. Approximately one of every five human cancers is caused by infectious agents with an estimate of 1.9 million cases per year worldwide. Of these cancers, approximately 70% are caused by viruses such as human papillomavirus, hepatitis virus types B and C, Epstein-Barr virus, human herpesvirus 8, and human T cell leukemia/lymphoma virus. Recent evidence also suggests that the increased life expectancy of HIV-infected individuals on HAART may enhance the risk of developing both AIDS-defining and non-defining cancers. The mission of the Center of Excellence in HIV/AIDS and Cancer Virology (CEHCV), established within the NCI's Intramural Research Program, is to facilitate and rapidly communicate advances in the discovery, development and delivery of antiviral and immunologic approaches for the prevention and treatment of HIV infection, AIDS-related malignancies and cancer-associated viral diseases. Toward this end, NCI research on AIDS, HIV and HTLV has resulted in 488 new invention reports, 1043 patents, and 246 licenses, including didanosine (Videx), ddI generics, ddC (Hivid), and darunavir (Prestiva).
To learn about recent advances by Center researchers, click on the images above.
To learn more about the Center, view our brochure.
Norman P. Salzman Memorial Award and Symposium
November 30, 2012
8:40am-12:35pm
Natcher Conference Center, main auditorium
Bethesda, MD
The NIH Virology Interest Group and the Foundation for the NIH are pleased to announce the 2012 Norman P. Salzman Award and Symposium. The Symposium is held in conjunction with the presentation of the annual Norman P. Salzman Award, which recognizes outstanding accomplishments by a post-doctoral fellow or research trainee working in the field of virology at the NIH or FDA. For more information and to register click here
CEHCV Bethesda Think Tank
November 30, 2012
1:30pm-5:00pm
Natcher Conference Center Bldg 45 Room E1/E2
Bethesda, MD
The CEHCV annual Bethesda Think Tank meeting is a publicly held conference focused on the exchange of information about the biology of cancer-associated viruses. This year's Think Tank will be a half-day meeting and will immediately follow the annual Saltzman Award Symposium. The meeting will also feature a poster session and abstracts of 300 or fewer can be submitted to Teresa Habina <habinata@mail.nih.gov> by November 9. For more information click here
HIV Drug Resistance Program Conference: Trafficking of Viral Macromolecules
December 14, 2012
1:00-5:10PM
Conference center
Frederick National Laboratory for Cancer Research
Frederick, Maryland
This conference will showcase the latest findings on viral macromolecule trafficking. The goal is to gain insights into the mechanisms of macromolecule trafficking in a variety of virus systems, which will aid in the development of new and more effective antiviral therapies. For more information click here
